Clinical trial registry record

Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 7, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05125081
Last registry update
January 7, 2026
Status
Completed
Phase
Phase 2
Sponsor
Shanghai Jiao Tong University School of Medicine
Enrollment
120
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
120
Population
ALL · 65 Years to 75 Years
Duration
2022-01-25 to 2024-12-25
Intervention
Liuwei Dihuang Pill (marketed product in China); Liuwei Dihuang Pill（placebo ）
Comparator
placebo group
Outcomes measured
Change in PB-Max after 48 weeks of treatment — 48 weeks; Change in Speech recognition threshold (SRT) after 24 weeks and 48 weeks of treatment — 24 weeks，48 weeks; Change in Pure Tone Average (PTA) after 24 weeks and 48 weeks of treatment — 24 weeks，48 weeks; Change in Shen (Kidney)-Yin Deficiency Syndrome Questionnaire after 12 weeks，24 weeks，36 weeks and 48 weeks of treatmen…; Change in Tinnitus Handicap Inventory（THI）after 12 weeks，24 weeks，36 weeks and 48 weeks of treatment — 12 weeks，24 week…; Change in Mini-mental State Examination (MMSE) after 12 weeks，24 weeks，36 weeks and 48 weeks of treatment — 12 weeks，24…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Hearing ageing · 100%Title contains controlled term: presbycusis. Abstract contains controlled term: presbycusis. Source terminology contains: age-related hearing loss, presbycusis. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

hearing aging
Open primary sourceExport JSON